

A381

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) EP 1 371 360 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
25.05.2005 Bulletin 2005/21

(51) Int Cl.7: **A61K 9/00, B65D 35/24,**
A61J 7/00, B65D 47/30,
B65D 47/24

(21) Application number: 03016997.3

(22) Date of filing: 10.03.1994

(54) Device for containing a pharmaceutical composition

Verpackung für Pharmazeutika

Emballage pour compositions pharmaceutiques

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE

(30) Priority: 11.03.1993 US 29443
30.08.1993 US 114315

(43) Date of publication of application:
17.12.2003 Bulletin 2003/51

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
94301695.6 / 0 614 659

(73) Proprietor: Taro Pharmaceutical Industries Ltd.
Haifa Bay 26110 (IL)

(72) Inventor: Ross, Malcom Stewart Frank
Tel Aviv (IL)

(74) Representative: Domenego, Bertrand et al
Cabinet Lavoix
2, place d'Estienne d'Orves
75441 Paris Cedex 09 (FR)

(56) References cited:

EP-A- 0 189 722	EP-A- 0 379 147
EP-A- 0 479 005	US-A- 2 559 070
US-A- 3 145 886	US-A- 4 091 965
US-A- 4 284 649	US-A- 4 427 681
US-A- 5 137 183	

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 371 360 B1

EP 1 371 360 B1

Description**Background of the Invention**

[0001] This invention is concerned with new formulations of orally active pharmaceutical agents and a device for administration thereof. More particularly this invention is concerned with formulations in semisolid form for oral administration of pharmaceutical agents used for systemic treatment, preferably contained in a single dose packet or in a multi-dose measuring device which can be used to measure as well as to administer the formulation, and to a childproof closure useful for the device.

[0002] Heretofore, pharmaceutical agents for systemic treatment by oral administration have generally been formulated in solid form as pills or capsules or in liquid form. Children, the elderly and people with motor problems often have problems swallowing pills and capsules. It is also difficult to administer medicine in liquid form to children, even when the liquid has been thickened to a syrup, and the elderly and those with motor problems also have difficulty with the self-administration of liquid, especially when it is necessary to measure a specific unit dose.

[0003] Important requirements for a non-solid pharmaceutical formulation for oral administration include palatability to children and adults, stability, i.e. a long shelf life, compatibility of formulation components with active agent and desirably, ease of administration of the required dose.

[0004] Pharmaceutical preparations in semisolid form for topical application are well known in the art. Such preparations include gels, pastes, creams and ointments for use on the skin, teeth and mucous membranes. Antacids and anti-ulcer agents in suspension and gel form for coating the mucous lining of the stomach are also well known in the art.

[0005] In a few instances, systemically useful pharmaceutical agents have been incorporated into gelled vehicles, as for example those disclosed in U.S. Pat. Nos. 4,305,933, 4,576,645 and 4,883,660. However, these vehicles all suffer from one or more disadvantages, such as the presence of a component which is undesirable for administration to children and/or is incompatible with many pharmaceutical agents, the presence of an emulsion which is difficult to manufacture and tends to be unstable and/or inadequate viscosity.

[0006] There is a need for an economical formulation of systemic pharmaceutical agents in easily administered form, as well as a need for easily administered non-spill pharmaceutical formulations which can be measured and administered effortlessly to children and by adults with motor problems. There is also a need for a simple to use and easily manufactured device for the measurement and administration of a predetermined dose of a pharmaceutical agent and also for a device of this type which is substantially tamper-proof in so far as young children or individuals with limited mental capacity are concerned.

[0007] While devices for dispensing a measured amount of a composition have been disclosed, for example in U.S. Pat. Nos. 3,104,032 and 3,383,081, these devices tend to be complicated and are not completely satisfactory for easy delivery and administration of a measured amount of a pharmaceutical composition.

[0008] US-4 091 965 discloses a container for flowable materials. A cover of the container has an elongated hollow extension terminating in a feeder or dispenser portion.

[0009] US-2 559 070 discloses a dispensing closure for collapsible containers. EP-479 005 discloses a gel composition in a container.

Summary of the Invention

[0010] An object of the invention is the provision of pharmaceutical agents useful for systemic treatment by the oral route in a form which is convenient to administer to children and which is convenient for self administration of aging adults, as well as adults with motor problems.

[0011] Another object of the invention is the provision of pharmaceutical agents useful for systemic treatment by oral administration in a composition which is provided in a device from which it is particularly easy to administer and convenient to measure single dosage units of the composition.

[0012] A further object of the invention is the provision of pharmaceutical agents useful for systemic treatment by oral administration in a form which avoids the problems of liquid formulations, such as spillage.

[0013] Another important object of the invention is the provision of a device for easily administering pharmaceutical formulations in semisolid form in dosage units.

[0014] Still another important object of the invention is the provision of a device for easily administering pharmaceutical formulations in semisolid form in dosage units which is substantially tamper proof by young children or individuals with limited mental capacity.

[0015] A further important object of the invention is the provision of a childproof closure useful for a device for holding pharmaceutical formulations.

[0016] These and other objects of the invention are achieved by the invention set forth below.

[0017] It has been discovered that pharmaceutical agents in semisolid form, such as a gel or paste, are much easier

EP 1 371 360 B1

to administer to children than liquid and solid dosage forms and are much easier for an aging adult or a adult with motor problems to measure than a liquid and in some cases are easier to swallow than a pill or capsule. It has also been discovered that such compositions can be desirably packaged in a single dosage form or in a multi-dose device which contains measuring and administration means.

5 [0018] According to the invention, a pharmaceutical agent useful for oral administration to treat an illness systemically is provided as a semisolid in gel or suspension form, such as a paste, in a composition containing the pharmaceutical agent and a pharmaceutically acceptable vehicle comprising a thickening agent and a liquid base compatible with the pharmaceutical agent and thickening agent in which the pharmaceutical agent is soluble.

10 [0019] In a preferred embodiment of the invention, a single dose of the semisolid pharmaceutical composition is contained in a flexible packet which can be opened by tearing or cutting.

[0020] In another preferred embodiment of the invention, a device for containing the semisolid pharmaceutical composition is provided which comprises a squeezable container with means for measuring and administering therefrom a single dose of the semisolid composition of the invention and resealing the container thereafter.

15 [0021] In a particularly preferred embodiment of the invention, a device for containing multiple doses and measuring a single dose of the semisolid composition of the invention comprises a squeezable container for holding the pharmaceutical composition having an open neck with exterior threads for attaching a cap thereto and a cap with interior threads suitable to engage the outer threads of the neck of the squeezable container, a spoon having a shaft with channel means fixed in the cap so that the bowl-shaped end of the spoon projects outside the cap and the shaft projects into the cap and the channel means are in alignment with the open neck of the squeezable container and sealing means in said cap positioned to seal the container when the cap is fully closed and to provide space for the contents of the container to flow through the channel means into the spoon in response to pressure on the container when the cap is partially opened, whereby contents of the squeezable container can be squeezed into the bowl-shaped end of the spoon and administered therefrom.

20 [0022] The device of the invention can be resealed after use by including any of a variety of resealing means in the cap, such as pin inside the cap which rests against and doses the neck of the squeezable container when the cap is tightened after use; a rotatable or pivotable valve and a spring activated step valve, which allow passage of the semisolid composition from the tube to the spoon when open and seal off the contents of the squeezable container when in the closed position.

25 [0023] Another embodiment of the invention is a closure which cannot be normally opened normally by a child, which is referred to herein as a childproof closure, and which can be used in the device of the invention.

30 Brief Description of the Drawings

[0024]

35 Figure 1 illustrates a closed tube containing a semisolid composition of the invention; Figure 2 illustrates a replacement cap of the invention for the tube of Figure 1 equipped with a spoon for measuring and administering a dose of the semisolid composition of the invention; Figure 3 illustrates a tube containing the semisolid composition of the invention with attached replacement cap equipped with a spoon and Figure 4 shows a section of Figure 3 along lines 4-4.

40 Figure 5 illustrates an alternate device of the invention having a resealable cap equipped with a spoon. Figure 6, which illustrates the cap in closed position and Figure 7, which illustrates the cap in open position with semisolid composition of the invention being squeezed into the spoon, show sections of the cap of Figure 5 taken along the line 7-7.

45 Figure 8 is a perspective view of a cap, partially broken away to reveal the inner structure of the resealing mechanism of another embodiment of the device of the invention; Figure 9 shows a section of the cap of Figure 8 taken along the line 9-9.

50 Figure 10 is a perspective view of a cap, partially broken away to reveal the inner structure of the pivoting valve resealing mechanism of another embodiment of the device of the invention; Figure 11 is a partial side view of the pivoting valve with a phantom outline of the pivoting valve in the upright closed position shown by the dash-dot line and the open position by the dashed line.

Figure 12 is a perspective view of a cap, partially broken away to reveal the inner structure of a cap with a spring-activated mechanism of another embodiment of the device of the invention; Figure 13 shows a section of Figure 13 along the line 13-13.

55 Figure 14 is another perspective view of a cap, partially broken away to reveal the inner structure of resealing means with a spring-activated mechanism of another embodiment of the device of the invention, which is further provided with means to prevent access of the contents of the tube to children and to prevent tampering; Figure 15 shows a section of Figure 14 taken along line 15-15 which illustrates means to prevent access of the contents of

EP 1 371 360 B1

the tube to children and Figure 16 also shows a section of Figure taken along line 15-15 which illustrates means to prevent tampering of the device prior to intended use.

Description of the Invention

[0025] The pharmaceutical compositions of the invention are comprised of a pharmaceutical agent in an effective amount for systemic treatment by oral administration in admixture with a pharmaceutically acceptable vehicle comprising a thickening agent in a amount which provides a semisolid, such as a gel or a paste suspension. The semisolid has a Brookfield viscosity at of above 2500 cps, preferably 2500 to 70,000 cps more preferably 3500 - 65,000 cps and most preferably about 7,500 - 40,000 cps. In the present application, viscosity refers of Brookfield viscosity, measured at 25°C and a spindle speed of 10 rpm; unless otherwise noted.

[0026] The semisolid form is generally a gel or a paste suspension which has the required viscosity to be squeezed easily through a small orifice similarly to tooth paste, dermatological creams, ointments and the like. The particular viscosity above 2500 cps is not critical as long as it fulfills the requirement of being a semisolid which is squeezable through a relatively small orifice such as that usual at the mouth of a flexible tube.

[0027] In general, the viscosity of the compositions of the invention can be varied by the choice and amount of thickening agent used from about 2500 cps to any greater viscosity which still permits the composition to be readily squeezed through a relatively narrow orifice, i.e. of the order of about 1 to 5 mm in diameter, such as that provided by the opening of a single dose packet or a seal-a-spoon device of the invention.

[0028] By systemic treatment is meant treatment which affects the body as a whole, as compared to topical treatment, which affects only that part of the body to which it is applied, i.e. skin, teeth or particular mucous membrane, such as the lining of the stomach.

[0029] Orally active pharmaceutical agents which may be present in the semisolid compositions of the invention are those useful for systemic treatment by oral administration and include for example:

analgesics, such as acetaminophen, codeine, aspirin and dihydrocodeinone;
anti-inflammatory agents, such as ibuprofen, naproxen and diclofenac;
anti-histamines including H₁-blockers, such as chlorpheniramine, terfenadine, loratidine, astemizole and cetirizine and H₂-blockers, such as cimetidine and ranitidine;
anti-infectives including: antibacterials such as sulfa drugs, i.e. sulfisoxazole; quinolones, i.e. ciprofloxacin and ofloxacin; tetracyclines, i.e. tetracycline; anti-virals, i.e. acyclovir and amantadine and anti-fungals, i.e. fluconazole; bronchodilators, such as albuterol, metaproterenol and theophylline;
cough suppressants, such as dextromethorphan;
expectorants, such as guaifenesin;
CNS active agents, including: hypnotics, such as triazolam; sedatives, such as phenobarbital; tranquilizers, such as chlorpromazine and diazepam; antidepressants, such as fluoxetine and nortriptyline; anticonvulsants, such as carbamazepine and ethosuximide and anti-Parkinson's agents, such as L-DOPA;
cardiovascular drugs including: diuretics, such as hydrochlorothiazide; anti-hypertensives including: beta-blockers, such as propranolol; ACE inhibitors, such as captopril and enalapril; calcium channel blockers, such as diltiazem;
anti-anginals, same as anti-hypertensive agents; cardiac glycosides, such as digoxin;
antineoplastics, such as 5-fluorouracil and cyclophosphamide;
cholesterol-lowering agents such as lovastatin;
anti-emetics, such as metoclopramide;
vitamins, such as A, B₁, B₆, C, D₃ and E;
minerals, such as iron, calcium and zinc salts and fecal softeners, such as docusate.

[0030] Useful pharmaceutical agents of course include pharmaceutically acceptable salts and esters of the named compositions:

[0031] The semisolid compositions of the invention have a liquid base, which is a palatable pharmaceutically acceptable solvent, preferably a solvent which dissolves the active pharmaceutical agent. Preferred solvents include water, propylene glycol, glycerin and mixtures thereof. In some instances it may be necessary to include a compound which is effective to solubilize the active pharmaceutical agent in the solvent, for example, lactic acid is used in an aqueous formulation of ciprofloxacin hydrochloride to solubilize this active ingredient.

[0032] According to the invention, any pharmaceutically acceptable thickening agent can be used in the compositions of the invention, providing of course that the thickening agent is compatible with the active agent and the solvent base. Examples of useful thickening agents include natural occurring thickening agents or thickening agents derived from naturally occurring materials, such as starch and starch derivatives, for example modified starch; cellulose derivatives, for example sodium carboxymethylcellulose, microcrystalline cellulose and hydroxypropyl cellulose; acacia; traga-

EP 1 371 360 B1

canth, pectin and gelatin, as well as totally synthetic thickening agents, such as polyethylene glycol and water soluble carboxyvinyl polymers, such as those sold under the names of carbomer and Carbopol™, which is produced by B. F. Goodrich Chemical Group. Gelatin, cellulose derivatives, polyethylene glycols and water soluble carboxyvinyl polymers are preferred.

5 [0033] A sweetener is added to the composition of the invention in an amount necessary to make the semisolid palatable.

[0034] Ingredients such as flavoring, coloring matter, filler, preservative, buffer, sodium chloride and carriers usual in pharmaceutical compositions can also be present in the semisolid compositions of the invention.

10 [0035] In one preferred embodiment, a single dose of the semisolid pharmaceutical composition of the invention is contained in a small flexible packet or sachet which is readily torn or cut so that the contents thereof can be squeezed directly into the mouth, or if preferred, into another vehicle for oral administration. Such containers are commonly used, for example, for single servings of condiments and can be made of flexible plastic and/or of non-corrosive metal film.

15 [0036] In another preferred embodiment, multiple doses of the semisolid pharmaceutical composition of the invention are contained in a device of the invention referred to as a seal-a-spoon which is described in detail below and in the accompanying drawings.

20 [0037] With reference to Figures 1-4, the tube 1 containing a semisolid pharmaceutical composition of the invention is provided with the cap 3, which can be replaced by the cap 5 shown in Figure 2. The device with attached cap 5 is illustrated in Figures 3 and 4. As is usual, the outside of neck 2 of tube 1 and the inside of cap 5 are provided with corresponding threads, so that the cap can be fixed to the neck of the tube. A spoon shaped projection 7, which is preferably sized to contain a single unit dose of the semisolid composition of the invention contained in tube 1, is connected to the cap 5 by means of the shaft 9, which is provided with a channel 11 adapted to be aligned with the opening of the neck 2 of tube 1, so that the semisolid composition in tube 1 can be squeezed directly from the tube 1 through the channel 11 into the spoon shaped projection 7 and administered therefrom.

25 [0038] Seal-a-spoon devices of the invention wherein the cap containing the spoon-shaped projection is provided with resealable means are illustrated in Figures 5-15. A seal-a-spoon device of the invention with a "child-proof" mechanism and also with tamper-proof means is illustrated in Figures 14-16.

30 [0039] As illustrated in Figures 5-7, the spoon shaped projection 7 set in cap 5a by shaft 9 is provided with a pin 13 which projects into the inside of the cap 5a and is adapted to rest against the neck 2 of tube 1 and seal the tube when the cap 5a is in the fully closed position illustrated in Figure 6. When the cap is rotated a few notches, as illustrated in Figure 7, but not separated from tube 1, the pin no longer rests against the neck of tube 1, which is then unsealed and the semisolid composition in tube 1 can be readily forced through the channel 15, which is present between the shaft 9 and the pin 13, into the projecting spoon 7 and administered directly therefrom.

35 [0040] Another embodiment of the seal-a-spoon device of the invention is illustrated in Figures 8 and 9 wherein the cap 5c is provided with the rotating valve or stopcock 17 having a channel 19 which can be aligned as shown with the channel 11 in the shaft 9 (not shown) or turned to prevent the flow of semisolid composition from the tube 1, as indicated by the dashed line in Figure 9.

40 [0041] Still another embodiment of the seal-a-spoon device of the invention is illustrated in Figures 10 and 11, wherein the cap 5d is provided with the pivoting valve 21 connected to the pivoting hinge 23. The pivoting valve 21 has a channel 25 which is in alignment with the channel 11 of the shaft 9 (not shown) when in the down position illustrated, allowing the flow of semisolid composition from the tube 1 (not shown) into the spoon 7; when the pivoting valve 21 is moved to the upright position, as shown by the dash-dot line of Figure 11, with the aid of the protuberance 27, the contents of the tube 1 are resealed.

45 [0042] Further embodiments of the seal-a-spoon device of the invention are illustrated in Figures 12-15. As shown in Figures 12 and 13, the cap 5e is provided with a spring biased step cylinder 29 having a channel 31; the spring 33 is held in place by a retaining member 35, such as a screw plug. When the step cylinder 29 is in the normal upright position, the contents of tube 1 (not shown) are sealed; when the step cylinder 29 is pressed to compress the spring 33, so that the channel 31 is in alignment with the channel 11 of the shaft 9 (not shown), the contents of the tube 1 (not shown) can be squeezed into the spoon 7.

50 [0043] A childproof and tamper proof seal-a-spoon device of the invention is illustrated in Figures 14-16, wherein the cap 5f is provided with a rotating spring biased step cylinder 37 having a channel 39 and also having on its side, near the top, the button 41. The cap 5f is also provided on its outside near the step cylinder 37, with a cavity 43 corresponding in size and shape to the button 41. When the step cylinder 37 is in the normal upright position, the contents of the tube 1 (not shown) are sealed. The step cylinder 37 cannot be depressed unless the button 41 is lined up with the cavity 43 in the cap 5f. In addition, the cavity in the cap 5f is initially sealed with a sheet of plastic 45. When the button is aligned with the cavity of corresponding shape in the cap 5f and pushed for the first time, the plastic sheet 45 is broken. An unbroken sheet 45 means that the cap 5f has not been previously used or tampered with. The cap 5f is a permanent cap which can not be removed by normal means or which has special safeguards against removal.

EP 1 371 360 B1

[0044] Since the rotating spring biased cylinder 37 cannot be depressed unless the button 41 is first lined up with the cavity 43 in the cap 5f, three different motions are required before the contents of the tube 1 (not shown) can be caused to flow into the spoon 7: aligning the button 41 with the cavity 43 by rotating the step cylinder 37, depressing the step cylinder 37 to align the channel 39 with channel 11 and pressing on the tube 1 to effect the flow of semisolid composition from the tube to the spoon 7. Therefore, this embodiment of the seal-a-spoon device of the invention is considered to be child proof, as well as tamper proof.

[0045] The childproof closure illustrated in Figures 14, with or without (not illustrated) the projecting spoon, can be applied to other containers of medicine.

[0046] The following examples further illustrate the invention, but must not be construed as limiting the invention in any manner.

Example 1Acetaminophen Formulation Thickened with Polyethylene Glycols

[0047] Acetaminophen was dissolved in a minimum quantity of water and combined with propylene glycol, a mixture of polyethylene glycols (PEG 400, which has an average molecular weight of 800 and PEG 3350, which has an average molecular weight of 1600), preservative, sweetener and flavoring to provide the following composition in percent by weight.

PEG mixture	72
Acetaminophen	2.5
Propylene glycol	25
Methylparabens	0.22
Sodium Saccharin	0.2
Cherry essence	0.05
Red DC 33	0.005
Water	to 10

[0048] PEG mixtures were varied in the foregoing formula to provide compositions with different viscosities as shown in Table 1. The viscosities were measured by means of a Brookfield Viscometer at 20°C at a spindle speed of 20 to 100 rpm, depending on medium viscosity, or at 25°C at a spindle speed of 10 rpm. All of these compositions are useful as semisolids for oral administration and can be packed in single dose containers or in a multiple dose device of the invention.

Table 1

PEG 400 % by wt.	PEG 3350 % by wt	VISCOSITY CPS
60	40	62,640
70	30	39,280
80	20	25,040

Example 2Pseudoephedrine HCl Formulation Thickened with Polyethylene Glycols

[0049] Pseudoephedrine HCl (0.6%) is incorporated into a formulation base consisting of propylene glycol (25%), polyethylene glycols (73.5%) consisting of 75% PEG 400 and 25% PEG 3350, methyl parabens (0.22%) as a preservative, sodium saccharin (0.2%) as a sweetener, coloring and flavoring matter and water to make 100%.

[0050] This formulation provides a semisolid of desirable consistency and viscosity which can be packed in a single dose container or a seal-a-spoon device of the invention.

EP 1 371 360 B1

Example 3Acetaminophen Formulation Thickened with Carboxymethylcellulose

[0051] Acetaminophen (3.2%) is dissolved in a minimum quantity of water, glycerin (4%) and propylene glycol (25%) are added, after which, sodium saccharin (0.2%), methyl parabens (0.22%) and sodium carboxymethylcellulose (2.4%) are incorporated. Water is then added to make up 100%.

[0052] This formulation has a viscosity of 15,000 cps when measured in the same manner as the formulations of Example 1 and has a desirable semisolid consistency useful in packaging in single dose packets or in a multiple dose device of the invention.

Example 4Dextromethorphan Hydrobromide Formulation Thickened with Carbopol™

[0053] Dextromethorphan HBr (0.3%) is dissolved in a mixture of propylene glycol (25%), glycerin (4%) and Carbopol 934P (1%) as a thickening agent. Sweetener, preservative, flavor and color as in Example 1 are optionally added and the mixture is made up to 100% with water. This formulation exhibited a viscosity of 15,000 cps, when measured at 20-21°C as in Example 1 and had a desirable semisolid consistency suitable for packaging into single dose packets or in a seal-a-spoon device of the invention.

Example 5Dextromethorphan Hydrobromide Formulation Thickened with Gelatin

[0054] A pharmaceutical base is prepared by heating gelatin (2.5%) in water. Glycerin (4%), propylene glycol (25%) and dextromethorphan HBr (0.3%) are mixed into the gelatin solution. Sodium saccharin, methyl parabens, flavor and coloring matter are added as in Example 1 and the formulation is made up to 100% with water. This formulation exhibited a viscosity of 7500 which is suitable for packaging into single packets or a seal-a-spoon device of the invention. The viscosity of this formulation can be increased or decreased within the range of 6000 - 9000 cps by the addition of more or less gelatin.

Example 6Caridopa/Levidopa Formulation Thickened with Polyethylene Glycols

[0055] This is a non-aqueous formulation of caridopa/levidopa, which is useful as an anti-Parkinson medicament containing the following ingredients.

	weight %/volume
Carbidopa	0.100
Levidopa	1.000
PEG 400	56.524
PEG 3350	29.120
Propylene glycol	13.000
Saccharine Sodium	0.250
FDC Red #40	0.006

[0056] The formulation, which is prepared by combining the polyethylene glycols with propylene glycol, sweetener and coloring matter and then adding the active agents thereto, has a consistency suitable for use in a single dose packet or in a multiple dose device of the invention.

EP 1 371 360 B1

Example 7**Ibuprofen Formulation Thickened with Sodium Carboxymethylcellulose**

[0057] This semisolid suspension, which contains a non-steroidal anti-inflammatory agent, has the following ingredients and is prepared as indicated in Example 6 by combining the components of the semisolid vehicle and then adding the active constituent thereto.

	Weight %/Volume
Ibuprofen	2.000
Citric Acid	0.200
ETDA (Disodium)	0.020
FDC red #40	0.006
Cherry flavor	0.150
Vanilla flavor	0.050
Glycerin	20.000
Sodium carboxymethylcellulose	2.400
Sodium benzoate	0.100
Hydrogenated glucose	6.5
Purified water to	100 cc

[0058] The consistency of this formulation is suitable for use in a single dose packet or in a multiple dose device of the invention.

Example 8**Terfenadine Formulation Thickened with Sodium Carboxymethylcellulose**

[0059] A semisolid suspension of terfenadine, which is useful for the systemic treatment of allergies, is prepared as in Example 7 with the following ingredients.

	Weight %/Volume
Terfenadine	0.600
Sodium carboxymethylcellulose	2.400
Saccharin sodium	0.250
Hydrogenated glucose	65.000
Imitation raspberry flavor	0.150
Methyl paraben	0.200
Propyl paraben	0.050
FDC yellow #10	0.006
Purified water to	100 cc

[0060] The consistency of this formulation is suitable for use in a single dose packet or in a multiple dose device of the invention.

Example 9**Ranitidine Formulation Thickened with Sodium Carboxymethylcellulose and Hydroxypropyl Methylcellulose**

[0061] A semisolid formulation of ranitidine, which is an antagonist to histamine H₂ receptors, is prepared as in Example 7 with the following ingredients.

EP 1 371 360 B1

	Weight %/Volume
Ranitidine HCl (1.5% Ranitidine)	1.680
Dibasic sodium phosphate	0.030
Sodium carboxymethylcellulose	2.400
Hydroxypropyl methylcellulose	0.900
Peppermint flavor	0.100
FDC yellow #10	0.006
Monobasic potassium phosphate	0.020
Butyl paraben	0.180
Propyl paraben	0.500
Sodium chloride	0.050
Sorbitol 70%	30.000
Purified water to	100 cc

[0062] The consistency of this formulation is suitable for use in a single dose packet or in a multiple dose device of the invention.

Example 10

Ciprofloxacin HCl Formulation Thickened with Sodium Carboxymethylcellulose

[0063] A semisolid formulation of ciprofloxacin HCl, which is an antimicrobial agent, is prepared according to Example 7 with the following ingredients. In this formulation lactic acid is used to solubilize Ciprofloxacin HCl and the pH is adjusted to between 3.5 - 4.6 with HCl.

	Weight %/Volume
Ciprofloxacin HCl (200 mg Ciprofloxacin)	10.000
Saccharin sodium	0.250
Lactic acid	0.020
Sodium carboxymethylcellulose	2.400
Blackberry flavor	0.150
FDC red #40	0.006
FDC red # 5	0.002
Dextrose solution (5 %) in purified water to	100 cc

[0064] The consistency of this formulation is suitable for use in a single dose packet or in a multiple dose device of the invention.

Example 11

Triazolam Formulation Thickened with Sodium Carboxymethylcellulose

[0065] A semisolid formulation of triazolam, a hypnotic useful against insomnia, is prepared according to Example 7 with the following ingredients.

	Weight %/Volume
Triazolam	0.005
Sodium Benzoate	0.250
FDC yellow #6	0.008
Imitation orange flavor	0.120
Sodium Saccharin	0.220
Sodium carboxymethylcellulose	2.800

EP 1 371 360 B1

(continued)

	Weight %/Volume
Hydrogenated glucose	20.000
Purified water to	100 cc

[0066] The consistency of this formulation is suitable for use in a single dose packet or in a multiple dose device of the invention.

Example 12

Fluconazole Formulation Thickened with Sodium Carboxymethylcellulose

[0067] A semisolid formulation of fluconazole, a broad spectrum antifungal agent, was prepared as in Example 7 with the following ingredients.

	Weight %/Volume
Fluconazole	2.000
Sodium carboxymethylcellulose	2.400
FDC red #40	0.006
Cherry flavor	0.150
Sodium saccharin	0.240
Sodium chloride	0.050
Purified water to	100 cc

[0068] The consistency of this formulation is suitable for use in a single dose packet or in a multiple dose device of the invention. The formulation should be stored at a temperature below 25°C, but not lower than 5°C and must be supplied in a container made of polyvinyl chloride, Baxter Vialflex.

Example 13

Acyclovir Formulation Thickened with Sodium Carboxymethylcellulose and Microcrystalline Cellulose

[0069] A semisolid formulation of acyclovir, an anti-viral agent, is prepared according to Example 7, with the following ingredients.

	Weight %/Volume
Acyclovir	4.000
Methyl paraben	0.100
Propyl paraben	0.020
Sodium carboxymethylcellulose	2.400
Peppermint flavor	0.150
Glycerin	20.000
Microcrystalline cellulose	0.900
Sorbitol 70%	20.000
Sodium saccharin	0.30
FDC yellow #6	0.008
Purified water to	100 cc

[0070] The consistency of this formulation is suitable for use in a single dose packet or in a multiple dose device of the invention.

EP 1 371 360 B1

Example 14Fluoxetine HCl Formulation Thickened with Sodium Carboxymethylcellulose

[0071] A semisolid formulation of fluoxetine hydrochloride, and anti-depressant drug, is prepared according to Example 7 with the following ingredients.

	Weight %/Volume
Fluoxetine HCl	0.400
Benzoic acid	0.200
Imitation cherry flavor	0.150
FDC red #40	0.006
Glycerin	30.000
Sodium saccharin	0.200
Methyl paraben	0.160
Hydrogenated glucose	65.000
Sodium carboxymethylcellulose	2.500
Purified water to	100 cc

[0072] The consistency of this formulation is suitable for use in a single dose packet or in a multiple dose device of the invention.

Example 15Propranolol HCl Formulation Thickened with Sodium Carboxymethylcellulose and Microcrystalline Cellulose

[0073] A semisolid formulation of propranolol hydrochloride, which is a synthetic beta adrenergic receptor blocker, is prepared according to Example 7 with the following ingredients.

	Weight %/Volume	
	20 mg/5cc	40 mg/5cc
propranolol HCl	0.400	0.800
Cherry flavor	0.150	
Peppermint flavor		0.100
FDC red #40	0.006	
FDC yellow #6		0.008
Microcrystalline cellulose	0.900	0.900
Sodium carboxymethylcellulose	2.400	2.400
Methyl paraben	0.200	0.200
Propyl paraben	0.050	0.050
Sodium saccharin	0.250	0.250
Purified water to	100 cc	100 cc

[0074] The consistency of this formulation is suitable for use in a single dose packet or in a multiple dose device of the invention.

Example 16Enalapril Maleate Formulation Thickened with Sodium Carboxymethylcellulose

[0075] A semisolid formulation of enalapril maleate, which is useful for treatment of hypertension and heart failure, is prepared according to Example 7 with the following ingredients.

EP 1 371 360 B1

	Weight %/Volume
Enalapril maleate	0.100
FDC red #40	0.007
Saccharin sodium	0.250
Imitation cherry flavor	0.150
Sodium carboxymethylcellulose	2.800
Methyl paraben	0.220
Purified water to	200 cc

[0076] The consistency of this formulation is suitable for use in a single dose packet or in a multiple dose device of the invention.

Example 17

Diltiazem HCl Formulation Thickened with Sodium Carboxymethylcellulose, Hydroxypropyl Cellulose and Polyethylene Glycol

[0077] A semisolid formulation of diltiazem hydrochloride, which is a calcium antagonist, is prepared according to Example 7 with the following ingredients.

	Weight %/Volume
Diltiazem HCl	0.600
FDC yellow #6	0.006
Peppermint flavor	0.100
Hydroxypropyl cellulose	0.900
Sodium carboxymethylcellulose	2.400
Hydrogenated glucose	60.000
Saccharin sodium	0.220
Polyethylene glycol 1500	10.000
Purified water to	100 cc

[0078] The consistency of this formulation is suitable for use in a single dose packet or in a multiple dose device of the invention.

Example 18

Lovastatin Formulation Thickened with Sodium Carboxymethylcellulose and Polyethylene glycol

[0079] A semisolid formulation of lovastatin, a cholesterol lowering agent, is prepared according to Example 7 with the following ingredients.

	Weight %/Volume
Lovastatin	0.200
Butylhydroxy toluene	0.200
Sodium carboxymethylcellulose	2.500
FDC red #40	0.006
Peppermint flavor	0.100
Sodium saccharin	0.250
Polyethylene glycol 1500	25.000
Methyl paraben	0.200
Purified water to	100 cc

EP 1 371 360 B1

Claims

1. A device for containing and measuring a unit dose of a pharmaceutical composition in semisolid form comprising a squeezable container (1) for holding the pharmaceutical composition having an outlet defining a flow channel for delivering said composition from the container and a closure means adapted to be connected to the outlet, the closure means comprising a spoon-shaped element (7) having a shaft (9) with channel means (11) connected thereto so that the bowl of the spoon-shaped elements projects from the closure means and the channel means are in fluid communication with the flow channel of the squeezable container and sealing means in said closure means positioned to seal the container when the closure means is fully closed and to provide space for the contents of the container to flow through the channel means into the spoon-shaped element in response to pressure on the container when the closure means is partially opened, whereby contents of the squeezable container can be squeezed into the bowl of the spoon-shaped element (7) and administered therefrom, wherein the sealing means comprises a rotatable spring biased step cylinder (37) positioned in said closure means, said rotatable spring biased step cylinder having channel means (39) and an outside button (41), said closure means being provided with a cavity (43) which matches the size and shape of said button so that said button can fit into said cavity, whereby the channel means allows passage of the composition from inside the squeezable container when said rotatable spring biased step cylinder is depressed and said rotatable spring biased step cylinder can be depressed only when said button is aligned with said cavity.

2. The device of claim 1 which further comprises a plastic (45) covering over said cavity (43) which prevents tampering with said device before use.

3. The device of claim 1 or 2 wherein the spoon is able to hold a unit dose of the semisolid composition present in the squeezable container.

4. An assembly comprising a pharmaceutical composition in semisolid form which comprises an effective amount of an orally active pharmaceutical agent useful for systemic treatment in combination with a pharmaceutical acceptable vehicle comprising a thickening agent in an amount effective to provide a Brookfield viscosity of 250 to 7000 Pa.s (2500 to 70,000 cps) at 25°C at a spindle speed of 10 rpm contained in the device defined in any of claims 1 to 3.

5. An assembly according to Claim 4 wherein the composition comprises a semisolid in the form of a gel or suspension containing an effective amount of an orally active pharmaceutical agent useful for systemic treatment in combination with a pharmaceutically acceptable vehicle consisting essentially of liquid base selected from a member of the group consisting of water, propylene glycol, glycerin and a combination therefore; thickening agent selected from a member of the group consisting of starch, sodium carboxymethyl cellulose, hydroxypropyl methyl cellulose, microcrystalline cellulose, tragacanth, acacia, pectin, gelatin, polyethylene glycol and carbomer in an amount effective to provide a Brookfield viscosity of 250 to 7,000 Pa.s (2,500 to 70,000 cps) and a consistency which allows the composition to be squeezed easily through an orifice of 0.1 mm to 5 mm in diameter; sweetener as necessary to make the semisolid palatable; and optionally, flavoring, coloring matter, filler, preservative, buffer, sodium chloride and carriers usual in pharmaceutical compositions.

6. An assembly according to claim 5, wherein the composition has a Brookfield viscosity of 350 to 6,500 Pa.s (3,500 to 65,000 cps) at 25°C at a spindle speed of 10 rpm.

7. An assembly according to any of claims 4 to 6, wherein the composition has a Brookfield viscosity of 750 to 4,000 Pa.s (7,500 to 40,000 cps) at 25°C at a spindle speed of 10 rpm.

8. An assembly according to any of claims 4 to 7 in which the pharmaceutical agent is selected from a member of the group consisting of an analgesic, non-steroidal anti-inflammatory, antihistamine, cough suppressant, expectorant, bronchodilator, anti-infective, CNS active drug, cardiovascular drug, antineoplastic, cholesterol-lowering drug, anti-emetic, vitamin, mineral supplement and fecal softener.

9. An assembly according to claim 8, in which the pharmaceutical agent is selected from a member of the group consisting of acetaminophen, aspirin, ibuprofen, diphenhydramine, dextromethorphan, guaifenesin, pseudoephedrine, carbidopa, levodopa, terfenadine, ranitidine, ciprofloxacin, triazolam, fluconazole, acyclovir, fluoxetine, enalapril, diltiazem, lovastatin and a pharmaceutically acceptable salt or ester thereof.

10. The assembly of any of claims 4 to 9 wherein the liquid base is selected from water, propylene glycol, glycerin or

EP 1 371 360 B1

a mixture thereof.

11. An assembly according to any of claims 4 to 10 wherein said composition includes a sweetener, preservative and optionally, flavouring matter, colouring matter, buffer, sodium chloride and solubilising agent for the orally active pharmaceutical agent.

Patentsprüche

1. Eine Vorrichtung zum Beinhalt und Abmessen einer Einheitsdosis einer pharmazeutischen Zusammensetzung in halbfester Form, die umfasst einen ausdrückbaren Behälter (1) zum Aufnehmen der pharmazeutischen Zusammensetzung, mit einer Austrittsöffnung, die einen Flusskanal für das Abgeben besagter Zusammensetzung aus dem Behälter definiert, und ein Verschlussmittel, das zum Anschluss an die Austrittsöffnung angepasst ist, wobei das Verschlussmittel ein löffelförmiges Element (7), das einen Schaft (9) mit damit verbundenem Durchflusssmittel besitzt, umfasst, so dass die Vertiefung des löffelförmigen Elementes aus dem Verschlussmittel herausragt und das Durchflusssmittel in flüssiger Verbindung mit dem Flusskanal des ausdrückbaren Behälters ist und das Dichtungsmittel in besagtem Verschlussmittel so angeordnet ist, um den Behälter abzudichten, wenn das Verschlussmittel voll geschlossen ist, und Raum für den Inhalt des Behälters bereitstellt, so dass dieser als Antwort auf Druck auf den Behälter, wenn das Verschlussmittel teilweise geöffnet ist, durch die Durchflusssmittel in das löffelförmige Element fließt, wobei der Inhalt des ausdrückbaren Behälters in die Vertiefung des löffelförmigen Elementes (7) gedrückt werden und davon verabreicht werden kann, wobei das Dichtungsmittel einen rotierbaren federgespannten Stufenzylinder (37) umfasst, der in besagtem Verschlussmittel angeordnet ist, wobei der rotierbare federgespannte Stufenzylinder ein Durchflusssmittel (39) und einen Außenknopf (41) besitzt und besagtes Verschlussmittel mit einem Hohlraum (43) ausgestattet ist, der der Größe und Form von besagtem Knopf entspricht, so dass besagter Knopf in besagten Hohlraum passen kann, wobei das Durchflusssmittel den Durchtritt der Zusammensetzung vom Innern des ausdrückbaren Behälters erlaubt, wenn besagter rotierbarer federgespannter Stufenzylinder heruntergedrückt wird und besagter rotierbarer federgespannter Schrittzylinder nur heruntergedrückt werden kann, wenn besagter Knopf mit besagtem Hohlraum ausgerichtet ist.

2. Die Vorrichtung nach Anspruch 1, die des Weiteren eine Plastikabdeckung (45) über besagtem Hohlraum (43) umfasst, die das Herumhandtieren mit besagter Vorrichtung vor der Verwendung verhindert.

3. Die Vorrichtung aus Anspruch 1 oder 2, wobei der Löffel eine Einheitsdosis der halbfesten Zusammensetzung, die in dem pressbaren Behälter vorhanden ist, aufnehmen kann.

4. Eine Anordnung, die in der Vorrichtung, die durch einen der Ansprüche 1 bis 3 definiert wird, enthalten ist, die eine pharmazeutische Zusammensetzung in halbfester Form umfasst, die eine wirksame Menge eines oral aktiven pharmazeutischen Wirkstoffes, der in Verbindung mit einem pharmazeutisch annehmbaren Träger für eine systemische Behandlung verwendbar ist, umfasst, der ein Verdickungsmittel in einer Menge, die wirksam ist, um eine Brookfield Viskosität von 250 bis 700 Pa.s (2500 bis 70.000 cps) bei 25°C bei einer Spindelgeschwindigkeit von 10 rpm bereitstellt.

5. Eine Anordnung gemäß Anspruch 4, wobei die Mischung ein halbfestes Material in der Form eines Gels oder einer Suspension umfasst, das enthält eine wirksame Menge eines oral wirksamen pharmazeutischen Wirkstoffes verwendbar für die systemische Behandlung in Kombination mit einem pharmazeutisch akzeptablen Träger, der im wesentlichen aus einer flüssigen Basis besteht, die aus einem Mitglied der Gruppe, die aus Wasser, Propylenglykol, Glycerin und einer Kombination davon besteht, ausgewählt wird; einem Verdickungsmittel, ausgewählt aus der Gruppe bestehend aus Stärke, Natriumcarboxymethylzellulose, Hydroxypropylmethylzellulose, mikrokristalliner Zellulose, Tragantgummi, Gummi arabicum, Pectin, Gelatine, Polyethylenglykol und Carbomer in einer wirksamen Menge, um eine Brookfield Viskosität von 250 bis 7000 Pa.s (2500 bis 70.000 cps) und eine Konsistenz bereitzustellen, die es der Zusammensetzung erlaubt, leicht durch eine Öffnung mit einem Durchmesser von 0,1 mm bis 5 mm gedrückt zu werden; Süßstoffe wie erforderlich, um das halbfeste Material genießbar zu machen; und optional Aromastoffe, Farbstoffe, Füllmittel, Konservierungsmittel, Puffer, Natriumchlorid und Trägerstoffe, die in pharmazeutischen Zusammensetzungen üblich sind.

6. Eine Anordnung gemäß Anspruch 5, wobei die Zusammensetzung eine Brookfield Viskosität von 350 bis 6500 Pa.s (3500 bis 65.000 cps) bei 25°C bei einer Spindelgeschwindigkeit von 10 rpm besitzt.

EP 1 371 360 B1

7. Eine Anordnung gemäß einem der Ansprüche 4 bis 6, wobei die Zusammensetzung eine Brookfield Viskosität von 750 bis 4000 Pa.s (7500 bis 40.000 cps) bei 25°C bei einer Spindelgeschwindigkeit von 10 rpm besitzt.

8. Eine Anordnung gemäß einem der Ansprüche 4 bis 7, in der der pharmazeutische Wirkstoff aus einem Mitglied der Gruppe, die aus einem Analgetikum, einem nicht-steroidalen Entzündungshemmer, einem Antihistaminikum, einem Antitussivum, einem Schleimlöser, einem Bronchodilatator, einem Antiinfektivum, einem ZNS-aktivem Medikament, einem kardiovaskulären Medikament, einem Cytostatikum, einem Cholesterol-verringernenden Medikament, einem Antiemetikum, Vitaminen, einem Mineralienpräparat und einem fäkalen Weichmacher besteht, ausgewählt wird.

9. Eine Anordnung gemäß Anspruch 8, in der der pharmazeutische Wirkstoff aus einem Mitglied der Gruppe, die aus Acetaminophen, Aspirin, Ibuprofen, Diphenhydramin, Dextromethorphan, Guaifenesin, Pseudoephedrin, Carbidopa, Levodopa, Terfenadin, Ranitidin, Ciprofloxacin, Triazolam, Fluconazol, Aciclovir, Fluoxetin, Enalapril, Diltiazem, Lovastatin und einem pharmazeutisch akzeptablen Salz oder Ester davon besteht, ausgewählt wird.

10. Die Anordnung nach einem der Ansprüche 4 bis 9, wobei die flüssige Basis aus Wasser, Propylenglykol, Glycerin oder einer Mischung davon ausgewählt wird.

11. Eine Anordnung gemäß einem der Ansprüche 4 bis 10, wobei besagte Zusammensetzung einen Süßstoff, ein Konservierungsmittel und optional einen Aromastoff, einen Farbstoff, einen Puffer, Natriumchlorid und Lösungsmittel für den oral aktiven pharmazeutischen Wirkstoff beinhaltet.

Revendications

1. Dispositif pour contenir et mesurer une dose unitaire d'une composition pharmaceutique sous forme semi-solide, comprenant un récipient compressible (1) pour contenir la composition pharmaceutique, ayant une sortie définissant un canal d'écoulement pour distribuer ladite composition à partir du récipient et un moyen de fermeture adapté pour être connecté à la sortie, le moyen de fermeture comprenant un élément en forme de cuiller (7) ayant un arbre (9) avec un moyen formant canal (11) connecté à celui-ci de sorte à ce que le cuilleron de l'élément en forme de cuiller fasse saillie à partir du moyen de fermeture et que le moyen formant canal soit en communication fluide avec le canal d'écoulement du récipient compressible, et un moyen d'obturation hermétique dans ledit moyen de fermeture positionné pour obturer hermétiquement le récipient lorsque le moyen de fermeture est complètement fermé et pour fournir l'espace pour que le contenu du récipient s'écoule par le moyen formant canal dans l'élément en forme de cuiller en réponse à la pression sur le récipient lorsque le moyen de fermeture est partiellement ouvert, grâce à quoi le contenu du récipient compressible peut être comprimé vers le cuilleron de l'élément en forme de cuiller (7) et administré à partir de celui-ci, dans lequel le moyen d'obturation hermétique comprend un piston rotatif à étage rappelé par un ressort (37), positionné dans ledit moyen de fermeture, ledit piston rotatif à étage rappelé par un ressort ayant un moyen formant canal (39) et un ergot extérieur (41), ledit moyen de fermeture étant prévu avec une cavité (43) qui s'adapte à la dimension et à la forme dudit ergot de sorte que ledit ergot puisse s'ajuster dans ladite cavité, grâce à quoi le moyen de canal permet le passage de la composition depuis l'intérieur du récipient compressible lorsque ledit piston rotatif à étage rappelé par un ressort est enfoncé et ledit piston rotatif à étage rappelé par un ressort peut être enfoncé seulement lorsque ledit ergot est aligné avec ladite cavité.

2. Dispositif selon la revendication 1, qui comprend en outre une matière plastique (45) recouvrant ladite cavité (43) qui empêche une altération dudit dispositif avant utilisation.

3. Dispositif selon la revendication 1 ou 2, dans lequel la cuiller est capable de contenir une dose unitaire de la composition semi-solide présente dans le récipient compressible.

4. Ensemble comprenant une composition pharmaceutique sous forme semi-solide qui comprend une quantité efficace d'un agent pharmaceutique oralement actif, utile pour un traitement systémique en combinaison avec un excipient pharmaceutique acceptable comprenant un agent épaississant dans une quantité efficace pour fournir une viscosité de Brookfield de 250 à 7 000 Pa.s (2 500 à 70 000 cps) à 25 °C à une vitesse de broche de 10 tours par minute contenue dans le dispositif défini selon l'une quelconque des revendications 1 à 3.

5. Ensemble selon la revendication 4, dans lequel la composition comprend un semi-solide sous la forme d'un gel ou d'une suspension contenant une quantité efficace d'un agent pharmaceutique oralement actif utile pour un

EP 1 371 360 B1

traitement systémique en combinaison avec un excipient pharmaceutiquement acceptable composé essentiellement d'une base liquide choisie parmi les éléments du groupe comprenant l'eau, le propylène glycol, la glycérine et une combinaison de ceux-ci ; un agent épaississant choisi parmi les éléments du groupe comprenant l'amidon, la carboxyméthylcellulose de sodium, l'hydroxypropylméthylcellulose, la cellulose microcristalline, l'adragante, la gomme arabique, la pectine, la gélatine, le polyéthylène glycol et un carbomère dans une quantité efficace pour fournir une viscosité de Brookfield de 250 à 7 000 Pa.s (2 500 à 70 000 cps) et une consistance qui permette de comprimer facilement la composition à travers un orifice de 0,1 mm à 5 mm de diamètre ; un édulcorant lorsque nécessaire pour rendre le semi-solide sapide ; et facultativement, une matière aromatisante, colorante, une charge, un conservateur, un tampon, du chlorure de sodium et des supports habituels dans les compositions pharmaceutiques.

6. Ensemble selon la revendication 5, dans lequel la composition a une viscosité de Brookfield de 350 à 6 500 Pa.s (3 500 à 65 000 cps) à 25 °C à une vitesse de broche de 10 tours par minute.

7. Ensemble selon l'une quelconque des revendications 4 à 6, dans lequel la composition a une viscosité de Brookfield de 750 à 4 000 Pa.s (7 500 à 40 000 cps) à 25 °C à une vitesse de broche de 10 tours par minute.

8. Ensemble selon l'une quelconque des revendications 4 à 7, dans lequel l'agent pharmaceutique est choisi parmi les éléments du groupe comprenant un analgésique, un anti-inflammatoire non stéroïdien, une anti-histamine, un antitussif, un expectorant, un broncho-dilatateur, un anti-infectieux, un médicament actif sur le système nerveux central (SNC), un médicament cardiovasculaire, un antinéoplasique, un médicament hypocholestérolémiant, un antiémétique, une vitamine, un supplément minéral et un laxatif.

9. Ensemble selon la revendication 8, dans lequel l'agent pharmaceutique est choisi parmi les éléments du groupe comprenant l'acétaminophène, l'aspirine, l'ibuprofène, la diphenhydramine, le dextrométhorphan, la guaifénésine, la pseudoéphédrine, la carbidopa, la lévodopa, la terfénaire, la ranitidine, la ciprofloxacine, le triazolam, le fluconazole, l'acyclovir, la fluoxétine, l'énalapril, le diltiazem, la lovastatine et un sel ou un ester pharmaceutiquement acceptable de ceux-ci.

10. Ensemble selon l'une quelconque des revendications 4 à 9, dans lequel la base liquide est choisie parmi l'eau, le propylène glycol, la glycérine ou un mélange de ceux-ci.

11. Ensemble selon l'une quelconque des revendications 4 à 10, dans lequel ladite composition comprend un édulcorant, un conservateur, et facultativement une matière aromatisante, une matière colorante, un tampon, du chlorure de sodium et un agent de solubilisation pour l'agent pharmaceutique oralement actif.

EP 1 371 360 B1

FIG. 1




FIG. 2




FIG. 3








FIG. 4



EP 1 371 360 B1



EP 1,371 360 B1

FIG. 8




FIG. 9




FIG. 10










FIG. 11

EP 1 371 360 B1



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.